Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed or Refractory NHL
NCT01421667Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2011
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of brentuximab vedotin in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Seagen Inc. Primary endpoints: Objective Response Rate at 3 years and Adverse Events at 3 years. Started Aug 2011; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01421667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421667.